蔚藍生物(603739.SH):濰坊蔚之藍擬增資引進國際投資者ADM Singapore
格隆匯10月18日丨蔚藍生物(603739.SH)公佈,公司全資子公司濰坊蔚之藍擬通過增資的方式引進國際投資者Archer Daniels Midland Singapore,Pte.Ltd.(簡稱“ADM Singapore”),蔚藍生物集團將同步增資。增資完成後,雙方持股比例各為50%。
濰坊蔚之藍增資後的註冊資本為2500萬美元-3000萬美元,具體金額在標的公司增資之前由雙方確定。雙方分期出資,首期出資2000萬美元,預計2022年年底繳付。
增資引入國際投資者的主要目的:中國益生菌市場發展前景巨大,2020年產品規模接近850億元。益生菌可以調整人體生理機能,具有改善腸道菌羣平衡以及提高機體免疫力等功能,廣泛應用於食品、保健品、護膚品等領域,擁有廣闊的市場前景和發展前途,屬於國家產業政策鼓勵發展的行業。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.